Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 2007; 99: 601-607.

Published: 1st January 2007

Authors: Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A et al.

Conclusion

Some 400 patients were included and randomized to two different adjuvant chemotherapy regimens. There was no benefit from intensive chemotherapy (which was completed in only 9.4 per cent of patients): overall 5-year survival was 52 vs. 50 per cent, relative risk 0.95, 95 per cent confidence interval 0.7 to 1.29.



 

Pubmed Link

Your comments

0 Comments